Pancreatic Cancer Kras Inhibitor Daroxanrecib and ALS RNA-Targeting Drug Tofersen: Phase 3 Trial Highlights on Science Friday

Summary at a glance

Science Friday presents two hopeful stories about new therapies for serious diseases. First, Dr Zev Weinberg discusses Daroxanrecib, a Kras targeted therapy for pancreatic cancer that, in a randomized phase 3 trial, improved tumor shrinkage and doubled survival compared with standard chemotherapy, and is under FDA review with potential to move earlier in treatment. The second story by Pam Belloc covers Tofersen for a rare genetic form of ALS caused by SOD1 mutations. The drug reduces the production of toxic SOD1 protein, with about 25% of treated patients stabilizing or gaining function. The discussion also touches on broader questions about who might benefit, safety, costs, and future trials in other ALS and Kras-driven cancers.

• Daroxanrecib targets Kras and showed dramatic improvements in pancreatic cancer in a phase 3 trial.
• The FDA is expected to review the drug for potential broader use beyond second-line therapy.
• Tofersen is a targeted ALS therapy for SOD1 mutations with meaningful stabilization or improvement in about a quarter of patients.
• Questions remain about access, cost, broader applicability, and future trials in earlier disease stages.

Pancreatic cancer and Kras targeted therapy Daroxanrecib

The podcast opens with Ira Flato introducing two promising medical advances. The first focuses on Daroxanrecib, a drug designed to block Kras, the dominant oncogene driving many cancers and especially prevalent in pancreatic cancer. Zev Weinberg, co director of UCLA Health's GI Oncology program, explains that Kras has been a difficult target for decades, and this drug represents a major shift by inhibiting Kras at its source and interrupting downstream signaling that fuels tumor growth. Early studies in patients with very advanced pancreatic cancer showed tumor shrinkage and longer-than-expected survival, which prompted accelerated development and a randomized phase 3 trial in which patients who had already received chemotherapy were assigned to standard chemotherapy or the Kras-targeted pill. The trial demonstrated a dramatic improvement in tumor control and survival, effectively doubling overall survival for the Daroxanrecib group compared with chemotherapy alone. Weinberg stresses that this is a breakthrough moment for pancreatic cancer, a disease in which previous targeted strategies have largely failed, and positions Kras as a potential common target across multiple cancer types.

Kras oncogene: breadth and therapeutic implications

Weinberg notes Kras mutations are present in up to 25% of all cancers, with Kras mutation driving pancreatic cancer in about 90% of cases. Blocking Kras has been an elusive goal for 50 to 60 years, marked more by failures than successes. The new drug is not a universal cure, but it stands as a proof of principle that blocking the source of Kras signaling can translate into meaningful tumor reduction and longer survival. The discussion broadens to the possibility of applying Kras inhibitors to other cancers such as lung and colorectal cancer, where Kras mutations are also common but where single-agent activity may differ, suggesting that combination strategies or cancer-specific contexts will influence effectiveness. The host and guest emphasize that the Kras oncogene may be a more critical driver in some cancers than in others, which could shape how broadly this class of drugs is used.

Clinical trial design, timing, and regulatory outlook

The phase 3 trial compared the Daroxanrecib arm to standard chemotherapy in advanced pancreatic cancer patients who had already undergone prior chemotherapy. Daroxanrecib significantly improved tumor shrinkage, disease control, and, most notably, survival compared with chemotherapy alone. Weinberg expresses optimism that the FDA review could be swift given the strength of the data, and he envisions moving the drug into earlier lines of pancreatic cancer and integrating it with other agents as studies progress. The host asks about frontline use versus sequencing after chemotherapy, and Weinberg suggests that the field is already planning to study Daroxanrecib and similar agents before surgery and in patients with less advanced disease, potentially shifting the current treatment paradigm if regulatory decisions align with trial outcomes.

ALS Tofersen: mechanism, outcomes, and access

The second part of the program shifts to Pam Belloc discussing Tofersen, a therapy for a rare genetic form of ALS caused by SOD1 mutations. Tofersen is a synthetic molecule that binds to the mutated SOD1 RNA, reducing production of the toxic SOD1 protein that contributes to motor neuron degeneration. The drug received accelerated approval in 2023, based on its ability to lower the misfolded SOD1 protein, with subsequent follow-up showing that roughly 25% of treated patients stabilized or improved—an outcome that is unusual in ALS. Belloc recaps how patients who had seen rapid functional decline, such as Amanda Sifford, experienced meaningful improvements including stronger muscles and better breathing, enabling activities like dancing that had been inaccessible for years. The podcast underscores that these gains, while not universal, represent a substantial shift in the ALS treatment landscape for this genetic subset of patients.

Targeted therapy in ALS: scope, limitations, and future directions

Tofersen currently targets about 2% of ALS cases with the SOD1 mutation, raising questions about broader applicability to other forms of ALS. Insurance coverage and upfront costs are noted as barriers to access, and there is ongoing debate about whether misfolded SOD1 plays a role in other ALS subtypes or if targeted therapy could be extended through misfolding pathways. The podcast mentions a small clinical trial exploring whether Tofersen could help non SOD1 ALS cases, based on observations of SOD1 misfolding in a subset of patients. Side effects include spinal inflammation, which can mimic ALS progression, but clinicians mitigate this with steroids during monthly intrathecal infusions. Belloc also describes an active trial examining whether treating people who carry the SOD1 mutation but are asymptomatic could delay onset, using neurofilament light chain as a biomarker trigger for intervention. This preventive angle highlights a broader strategy of targeting early disease processes in neurodegenerative disorders.

Implications for science journalism and patient care

The host closes by tying these stories to a broader conversation about how science journalism can illuminate breakthroughs that alter patient care. The discussions illustrate how drugs that precisely target disease-driving mechanisms can yield meaningful, real-world benefits even in historically intractable conditions. They also emphasize the challenges of translating these advances into widespread clinical practice in a way that is equitable and accessible, considering regulatory timelines, cost, and insurance coverage. The program concludes with a note about the show’s production and listener engagement, underscoring the ongoing need for science journalism to connect patients, families, researchers, and clinicians with the latest developments.